Partnership Will Provide Cell and Gene Therapy Industry with Fully Integrated Logistics and Manufacturing Services for Regenerative Medicine Products

该合作伙伴关系将为细胞和基因治疗行业提供再生医学产品的全面集成物流和制造服务

NASHVILLE, Tenn. and YOKOHAMA, Japan, June 20, 2024 /PRNewswire/ -- CryoPort, Inc. (NASDAQ: CYRX) ('Cryoport'), a global leader in supply chain solutions for the life sciences, and Minaris Regenerative Medicine, LLC ('Minaris'), a global contract development and manufacturing organization for cell and gene therapies, today announced a strategic partnership to provide fully integrated logistics and manufacturing services to biotechnology and pharmaceutical companies for regenerative medicine products to support the advancement of cell and gene therapies..

田纳西州纳什维尔和日本横滨，2024年6月20日/PRNewswire/--CryoPort，Inc.（纳斯达克：CYRX）（“CryoPort”）是生命科学供应链解决方案的全球领导者，Minaris再生医学有限责任公司（“Minaris”）是一家全球细胞和基因治疗合同开发和制造组织，今天宣布建立战略伙伴关系，为生物技术和制药公司提供全面集成的再生医学产品物流和制造服务，以支持细胞和基因治疗的进步。。

The collaboration combines Cryoport's extensive capabilities and experience in meeting the logistics needs of the life sciences industry and Minaris' expertise in contract manufacturing of regenerative medicine products including stem cells, gene therapy, biomaterials and engineered tissue.

。

Jerrell Shelton, CEO of Cryoport, commented, 'We look forward to partnering with Minaris to provide cohesive supply chain solutions and manufacturing services for regenerative medicine products, starting from the collection of cells and tissues all the way to the delivery of these critical products and services to patients.

Cryoport首席执行官杰雷尔·谢尔顿（Jerrell Shelton）评论道：“我们期待着与米纳里斯（Minaris）合作，为再生医学产品提供连贯的供应链解决方案和制造服务，从收集细胞和组织一直到向患者提供这些关键产品和服务。

This partnership perfectly aligns with our organization's commitment to support the medical community and the people it serves.'.

这种伙伴关系完全符合我们组织支持医学界及其服务人员的承诺。”。

Dr. Hiroto Bando, CEO of Minaris, added, 'Ensuring secure transport, including the use and operation of specialized containers, as well as quality assurance, is essential for regenerative medicine products. By partnering with Cryoport, a best-in-class company that has considerable resources in all these areas, we will collaborate to provide high-quality services tailored to the exact needs of our customers.

Minaris首席执行官Hiroto Bando博士补充道，“确保安全运输，包括专用容器的使用和操作，以及质量保证，对于再生医学产品至关重要。通过与Cryoport（一家在所有这些领域拥有大量资源的一流公司）合作，我们将合作提供高质量的服务，以满足客户的确切需求。

While this partnership is with Minaris' Japan-based branch, we will collaborate to ensure that we can provide services to customers across the entire Minaris group.'.

虽然这种合作关系是与Minaris的日本分公司建立的，但我们将进行合作，以确保我们能够为整个Minaris集团的客户提供服务。”。

About Cryoport, Inc.

关于Cryoport，Inc。

Cryoport, Inc. (Nasdaq: CYRX), is a global leader in supply chain solutions for cell & gene therapies that enable manufacturers, contract manufacturers (CDMO's), contract research organizations (CRO's), developers, and researchers to carry out their respective business with certainty. We provide a broad array of supply chain solutions for the life sciences industry.

Cryoport，Inc.（纳斯达克股票代码：CYRX）是细胞和基因治疗供应链解决方案的全球领导者，它使制造商、合同制造商（CDMO）、合同研究组织（CRO）、开发人员和研究人员能够确定地开展各自的业务。我们为生命科学行业提供广泛的供应链解决方案。

Through our platform of critical products and solutions including advanced temperature-controlled packaging, informatics, specialized bio-logistics services, bio-storage, bio-services, and cryogenic systems, we are 'Enabling the Future of Medicine™' worldwide, through our innovative systems, compliant procedures, and agile approach to superior supply chain management..

通过我们的关键产品和解决方案平台，包括先进的温控包装、信息学、专业的生物物流服务、生物存储、生物服务和低温系统，我们通过创新的系统、合规的程序和敏捷的供应链管理方法，在全球范围内“实现Medicine™的未来”。。

Its corporate headquarters, located in Nashville, Tennessee, is complimented by over 50 global locations in 17 countries, with key sites in the United States, United Kingdom, France, the Netherlands, Portugal, Germany, Japan, Australia, India, and China.

其公司总部位于田纳西州纳什维尔，在全球17个国家拥有50多个办事处，主要地点位于美国、英国、法国、荷兰、葡萄牙、德国、日本、澳大利亚、印度和中国。

For more information, visit www.cryoportinc.com or follow via LinkedIn at https://www.linkedin.com/company/cryoportinc or @cryoport on X, formerly known as Twitter at www.twitter.com/cryoport for live updates.

有关更多信息，请访问www.cryoportinc.com或通过LinkedIn关注https://www.linkedin.com/company/cryoportinc或@cryoport on X，以前称为Twitter，网址为www.Twitter.com/cryoport，用于实时更新。

About Minaris Regenerative Medicine Co., Ltd.

关于Minaris再生医学有限公司。

Minaris Regenerative Medicine is a global contract development and manufacturing organization (CDMO) for cell and gene therapies. Our vision is creating future cell therapy miracles together and we are committed to providing global manufacturing services, development solutions, and technologies for cell and gene therapies to improve society's well-being.

Minaris再生医学是一家针对细胞和基因疗法的全球合同开发和制造组织（CDMO）。我们的愿景是共同创造未来的细胞治疗奇迹，我们致力于提供全球制造服务、开发解决方案以及细胞和基因治疗技术，以改善社会福祉。

We offer our clients high value clinical and commercial manufacturing services, development solutions, and technologies. We are pioneers in the field with more than 25 years' experience providing outstanding quality and reliability. Our facilities in North America, Europe, and Asia allow us to supply patients worldwide with life-changing therapies.

我们为客户提供高价值的临床和商业制造服务、开发解决方案和技术。我们是该领域的先驱，拥有超过25年的经验，提供卓越的质量和可靠性。我们在北美、欧洲和亚洲的设施使我们能够为全世界的患者提供改变生活的疗法。

Minaris Regenerative Medicine is wholly owned by Resonac Holdings Corporation..

Minaris再生医学由Resonac Holdings Corporation全资拥有。。

For more information about Minaris, please visit https://www.rm.minaris.com/en/

有关Minaris的更多信息，请访问https://www.rm.minaris.com/en/

Forward-Looking Statements

前瞻性声明

Statements in this press release which are not purely historical, including statements regarding Cryoport's intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

本新闻稿中的声明不纯粹是历史性的，包括关于Cryoport的意图、希望、信念、期望、陈述、预测、计划或未来预测的声明，都是1995年《私人证券诉讼改革法案》含义内的前瞻性声明。

These forward-looking statements include, but are not limited to, those related to Cryoport's industry, business, long-term growth prospects, plans, strategies, acquisitions, future financial results and financial condition, such as Cryoport's outlook and guidance for full year 2024 revenue and the related assumptions and factors expected to drive revenue, projected growth trends in the markets in which the Cryoport operates, Cryoport's plans and expectations regarding the launch of new products and services, such as the expected timing and benefits of such products and services launches, Cryoport's expectations about future benefits of its acquisitions, and anticipated regulatory filings, approvals, label/geographic expansions or moves to earlier lines of treatment approved with respect to the products of Cryoport's clients.

这些前瞻性陈述包括但不限于与Cryoport的行业、业务、长期增长前景、计划、战略、收购、未来财务业绩和财务状况相关的陈述，如Cryoport对2024年全年收入的展望和指导，以及预计会推动收入的相关假设和因素，Cryoport运营市场的预计增长趋势，Cryoport关于推出新产品和服务的计划和预期，如此类产品和服务推出的预期时间和收益，Cryoport对其收购未来收益的预期，以及预期的监管备案、批准、标签/地理扩展或转移到与Cryoport客户的产品。

Forward-looking statements also include those related to Cryoport's anticipation that its revenue will progressively improve throughout the year, including anticipated acceleration of revenue from the Cryoport's Cell & Gene Therapy clients, Cryoport's expectations that MVE's cryogenic system sales will be challenged throughout the remainder of the year, the Cryoport's expectations of the long-term prospects of its Life Sciences Products business, including the anticipation of demand normalizing, which would allow Cryoport to benefit from its position as the global leader in this space, and Cryoport's planned initiatives to drive.

前瞻性陈述还包括与Cryoport预计其全年收入将逐步提高有关的陈述，包括Cryoport细胞与基因治疗客户收入的预期加速，Cryoport预计MVE的低温系统销售将在今年剩余时间受到挑战，Cryoport对其生命科学产品业务的长期前景的预期，包括对需求正常化的预期，这将使Cryoport受益于其在该领域的全球领导者地位，以及Cryoport计划采取的举措。

View original content to download multimedia:https://www.prnewswire.com/news-releases/cryoport-and-minaris-regenerative-medicine-form-strategic-partnership-to-support-advancement-of-cell-and-gene-therapies-302177700.html

查看原始内容以下载多媒体：https://www.prnewswire.com/news-releases/cryoport-and-minaris-regenerative-medicine-form-strategic-partnership-to-support-advancement-of-cell-and-gene-therapies-302177700.html

SOURCE Cryoport, Inc.

SOURCE Cryoport公司。

Company Codes: NASDAQ-SMALL:CYRX

公司代码：NASDAQ-SMALL：CYRX